BACKGROUND: High-dose treatment with autologous stem cell transplantation (ASCT) has become the standard of care for patients with myeloma below the age of 65 years. AIMS: We report an audit of 60 patients (median age: 52.5 years) who underwent ASCT in the National Bone Marrow Transplant centre in St James's Hospital in Dublin between 1997 and 2003 inclusive. METHODS: Clinical and laboratory data were retrieved from patient medical records and hospital information management systems. RESULTS: Thirty-six patients had IgG, 11 IgA, 1 IgD, 9 light chain and 3 non-secretory MM. Fifty-seven (95%) patients received anthracycline-corticosteroid combination chemotherapy prior to autografting. There was no transplant-related mortality (TRM). Complete (CR) and Partial Responses (PR) were seen in 16 (29.6%) and 29 (53.7%) of those evaluable (n = 54 (90%)). The actuarial Progression-Free (PFS) and Overall Survival (OS) rates at five years are 13% and 55% respectively. CONCLUSION: Centre outcome is comparable to published international series and supports the use of ASCT in the treatment of this malignancy.
BACKGROUND: High-dose treatment with autologous stem cell transplantation (ASCT) has become the standard of care for patients with myeloma below the age of 65 years. AIMS: We report an audit of 60 patients (median age: 52.5 years) who underwent ASCT in the National Bone Marrow Transplant centre in St James's Hospital in Dublin between 1997 and 2003 inclusive. METHODS: Clinical and laboratory data were retrieved from patient medical records and hospital information management systems. RESULTS: Thirty-six patients had IgG, 11 IgA, 1 IgD, 9 light chain and 3 non-secretory MM. Fifty-seven (95%) patients received anthracycline-corticosteroid combination chemotherapy prior to autografting. There was no transplant-related mortality (TRM). Complete (CR) and Partial Responses (PR) were seen in 16 (29.6%) and 29 (53.7%) of those evaluable (n = 54 (90%)). The actuarial Progression-Free (PFS) and Overall Survival (OS) rates at five years are 13% and 55% respectively. CONCLUSION: Centre outcome is comparable to published international series and supports the use of ASCT in the treatment of this malignancy.
Authors: C-K Lee; M Zangari; B Barlogie; A Fassas; F van Rhee; R Thertulien; G Talamo; F Muwalla; E Anaissie; K Hollmig; G Tricot Journal: Bone Marrow Transplant Date: 2004-04 Impact factor: 5.483
Authors: W I Bensinger; S D Rowley; T Demirer; K Lilleby; K Schiffman; R A Clift; F R Appelbaum; A Fefer; T Barnett; R Storb; T Chauncey; R T Maziarz; J Klarnet; P McSweeney; L Holmberg; D G Maloney; C H Weaver; C D Buckner Journal: J Clin Oncol Date: 1996-05 Impact factor: 44.544
Authors: A Badros; B Barlogie; E Siegel; C Morris; R Desikan; M Zangari; A Fassas; E Anaissie; N Munshi; G Tricot Journal: Br J Haematol Date: 2001-09 Impact factor: 6.998
Authors: A Badros; B Barlogie; E Siegel; J Roberts; C Langmaid; M Zangari; R Desikan; M J Shaver; A Fassas; S McConnell; F Muwalla; Y Barri; E Anaissie; N Munshi; G Tricot Journal: Br J Haematol Date: 2001-09 Impact factor: 6.998
Authors: A K Stewart; R Vescio; G Schiller; O Ballester; S Noga; H Rugo; C Freytes; E Stadtmauer; S Tarantolo; F Sahebi; P Stiff; J Meharchard; R Schlossman; R Brown; H Tully; M Benyunes; C Jacobs; R Berenson; M White; J DiPersio; K C Anderson; J Berenson Journal: J Clin Oncol Date: 2001-09-01 Impact factor: 44.544
Authors: S Lenhoff; M Hjorth; E Holmberg; I Turesson; J Westin; J L Nielsen; F Wislöff; L Brinch; K Carlson; M Carlsson; I M Dahl; P Gimsing; E Hippe; H E Johnsen; H Johnsen; J Lamvik; E Löfvenberg; I Nesthus; S Rödjer Journal: Blood Date: 2000-01-01 Impact factor: 22.113
Authors: J Anthony Child; Gareth J Morgan; Faith E Davies; Roger G Owen; Susan E Bell; Kim Hawkins; Julia Brown; Mark T Drayson; Peter J Selby Journal: N Engl J Med Date: 2003-05-08 Impact factor: 91.245
Authors: A Anagnostopoulos; A Aleman; Y Yang; M Donato; D Weber; R Champlin; T Smith; R Alexanian; S Giralt Journal: Bone Marrow Transplant Date: 2004-03 Impact factor: 5.483
Authors: G Tricot; S Jagannath; D Vesole; J Nelson; S Tindle; L Miller; B Cheson; J Crowley; B Barlogie Journal: Blood Date: 1995-01-15 Impact factor: 22.113